Low coenzyme Q10 levels in patients with acute cardiovascular disease are associated with long-term mortality.
Acute cardiovascular disease
Coenzyme Q10
Inflammation
Long-term mortality
Malnutrition
Journal
Heart and vessels
ISSN: 1615-2573
Titre abrégé: Heart Vessels
Pays: Japan
ID NLM: 8511258
Informations de publication
Date de publication:
Mar 2021
Mar 2021
Historique:
received:
06
01
2020
accepted:
04
09
2020
pubmed:
18
9
2020
medline:
15
7
2021
entrez:
17
9
2020
Statut:
ppublish
Résumé
Coenzyme Q10 (CoQ10) plays a potential role in the prevention and treatment of cardiovascular disease through improved cellular bioenergetics. Critical illness in the intensive care unit has been reported to be associated with decreased circulating CoQ10 levels, and we previously demonstrated the association of low CoQ10 levels with in-hospital mortality. However, the association of CoQ10 with the acute phase of cardiovascular disease and long-term mortality remains unclear. We enrolled 242 consecutive patients with cardiovascular disease admitted to the coronary care unit of Juntendo University Hospital to investigate the association between long-term mortality and serum CoQ10 levels. During a mean follow-up of 3.2 years, 58 patients died. The mean serum CoQ10 levels were significantly lower in the non-survivors than in the survivors (0.48 ± 0.27 vs. 0.58 ± 0.38 mg/L; p = 0.035). Compared with the patients with above-median CoQ10 levels (0.46 mg/L), the cumulative incidence of all-cause mortality was significantly higher in those with lower CoQ10 levels (p = 0.025). Multivariate Cox regression analysis further demonstrated that lower CoQ10 levels were associated with poor prognosis. Low serum CoQ10 levels during the acute phase of cardiovascular diseases were associated with long-term mortality in patients, suggesting the utility of low serum CoQ10 levels as a predictor and potential therapeutic target.
Identifiants
pubmed: 32939561
doi: 10.1007/s00380-020-01698-7
pii: 10.1007/s00380-020-01698-7
doi:
Substances chimiques
Biomarkers
0
Ubiquinone
1339-63-5
coenzyme Q10
EJ27X76M46
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
401-407Subventions
Organisme : JSPS KAKENHI
ID : JP15K00845
Organisme : JSPS KAKENHI
ID : JP16K00869
Références
Crane FL, Hatefi Y, Lester RL, Widmer C (1957) Isolation of a quinone from beef heart mitochondria. Biochim Biophys Acta 25:220–221
doi: 10.1016/0006-3002(57)90457-2
Tian G, Sawashita J, Kubo H, Nishio SY, Hashimoto S, Suzuki N, Yoshimura H, Tsuruoka M, Wang Y, Liu Y, Luo H, Xu Z, Mori M, Kitano M, Hosoe K, Takeda T, Usami S, Higuchi K (2014) Ubiquinol-10 supplementation activates mitochondria functions to decelerate senescence in senescence-accelerated mice. Antioxid Redox Signal 20:2606–2620
doi: 10.1089/ars.2013.5406
Mortensen SA, Rosenfeldt F, Kumar A, Dolliner P, Filipiak KJ, Pella D, Alehagen U, Steurer G, Littarru GP, Investigators QSS (2014) The effect of coenzyme Q10 on morbidity and mortality in chronic heart failure: results from Q-SYMBIO: a randomized double-blind trial. JACC Heart Fail 2:641–649
doi: 10.1016/j.jchf.2014.06.008
Alehagen U, Aaseth J, Alexander J, Johansson P (2018) Still reduced cardiovascular mortality 12 years after supplementation with selenium and coenzyme Q10 for four years: a validation of previous 10-year follow-up results of a prospective randomized double-blind placebo-controlled trial in elderly. PLoS ONE 13:e0193120
doi: 10.1371/journal.pone.0193120
Gao L, Mao Q, Cao J, Wang Y, Zhou X, Fan L (2012) Effects of coenzyme Q10 on vascular endothelial function in humans: a meta-analysis of randomized controlled trials. Atherosclerosis 221:311–316
doi: 10.1016/j.atherosclerosis.2011.10.027
Lee BJ, Huang YC, Chen SJ, Lin PT (2012) Effects of coenzyme Q10 supplementation on inflammatory markers (high-sensitivity C-reactive protein, interleukin-6, and homocysteine) in patients with coronary artery disease. Nutrition 28:767–772
doi: 10.1016/j.nut.2011.11.008
Bullon P, Roman-Malo L, Marin-Aguilar F, Alvarez-Suarez JM, Giampieri F, Battino M, Cordero MD (2015) Lipophilic antioxidants prevent lipopolysaccharide-induced mitochondrial dysfunction through mitochondrial biogenesis improvement. Pharmacol Res 91:1–8
doi: 10.1016/j.phrs.2014.10.007
Lee BJ, Tseng YF, Yen CH, Lin PT (2013) Effects of coenzyme Q10 supplementation (300 mg/day) on antioxidation and anti-inflammation in coronary artery disease patients during statins therapy: a randomized, placebo-controlled trial. Nutr J 12:142
doi: 10.1186/1475-2891-12-142
Folkers K, Vadhanavikit S, Mortensen SA (1985) Biochemical rationale and myocardial tissue data on the effective therapy of cardiomyopathy with coenzyme Q10. Proc Natl Acad Sci U S A 82:901–904
doi: 10.1073/pnas.82.3.901
Munkholm H, Hansen HH, Rasmussen K (1999) Coenzyme Q10 treatment in serious heart failure. BioFactors 9:285–289
doi: 10.1002/biof.5520090225
Keogh A, Fenton S, Leslie C, Aboyoun C, Macdonald P, Zhao YC, Bailey M, Rosenfeldt F (2003) Randomised double-blind, placebo-controlled trial of coenzyme Q, therapy in class II and III systolic heart failure. Heart Lung Circ 12:135–141
doi: 10.1046/j.1443-9506.2003.00189.x
Rosenfeldt F, Marasco S, Lyon W, Wowk M, Sheeran F, Bailey M, Esmore D, Davis B, Pick A, Rabinov M, Smith J, Nagley P, Pepe S (2005) Coenzyme Q10 therapy before cardiac surgery improves mitochondrial function and in vitro contractility of myocardial tissue. J Thorac Cardiovasc Surg 129:25–32
doi: 10.1016/j.jtcvs.2004.03.034
Dai YL, Luk TH, Yiu KH, Wang M, Yip PM, Lee SW, Li SW, Tam S, Fong B, Lau CP, Siu CW, Tse HF (2011) Reversal of mitochondrial dysfunction by coenzyme Q10 supplement improves endothelial function in patients with ischaemic left ventricular systolic dysfunction: a randomized controlled trial. Atherosclerosis 216:395–401
doi: 10.1016/j.atherosclerosis.2011.02.013
Kumar A, Singh RB, Saxena M, Niaz MA, Josh SR, Chattopadhyay P, Mechirova V, Pella D, Fedacko J (2007) Effect of carni Q-gel (ubiquinol and carnitine) on cytokines in patients with heart failure in the Tishcon study. Acta Cardiol 62:349–354
doi: 10.2143/AC.62.4.2022278
Kaikkonen J, Tuomainen TP, Nyyssonen K, Salonen JT (2002) Coenzyme Q10: absorption, antioxidative properties, determinants, and plasma levels. Free Radic Res 36:389–397
doi: 10.1080/10715760290021234
Lee BJ, Lin YC, Huang YC, Ko YW, Hsia S, Lin PT (2012) The relationship between coenzyme Q10, oxidative stress, and antioxidant enzymes activities and coronary artery disease. ScientificWorldJournal 2012:792756
pubmed: 22645453
pmcid: 3356738
Molyneux SL, Florkowski CM, George PM, Pilbrow AP, Frampton CM, Lever M, Richards AM (2008) Coenzyme Q10: an independent predictor of mortality in chronic heart failure. J Am Coll Cardiol 52:1435–1441
doi: 10.1016/j.jacc.2008.07.044
Alehagen U, Johansson P, Bjornstedt M, Rosen A, Dahlstrom U (2013) Cardiovascular mortality and N-terminal-proBNP reduced after combined selenium and coenzyme Q10 supplementation: a 5-year prospective randomized double-blind placebo-controlled trial among elderly Swedish citizens. Int J Cardiol 167:1860–1866
doi: 10.1016/j.ijcard.2012.04.156
Mortensen AL, Rosenfeldt F, Filipiak KJ (2019) Effect of coenzyme Q10 in Europeans with chronic heart failure: a sub-group analysis of the Q-SYMBIO randomized double-blind trial. Cardiol J 26:147–156
pubmed: 30835327
Shimizu M, Miyazaki T, Takagi A, Sugita Y, Yatsu S, Murata A, Kato T, Suda S, Ouchi S, Aikawa T, Hiki M, Takahashi S, Hiki M, Hayashi H, Kasai T, Shimada K, Miyauchi K, Daida H (2017) Low circulating coenzyme Q10 during acute phase is associated with inflammation, malnutrition, and in-hospital mortality in patients admitted to the coronary care unit. Heart Vessels 32:668–673
doi: 10.1007/s00380-016-0923-x
Shimamoto K, Ando K, Fujita T, Hasebe N, Higaki J, Horiuchi M, Imai Y, Imaizumi T, Ishimitsu T, Ito M, Ito S, Itoh H, Iwao H, Kai H, Kario K, Kashihara N, Kawano Y, Kim-Mitsuyama S, Kimura G, Kohara K, Komuro I, Kumagai H, Matsuura H, Miura K, Morishita R, Naruse M, Node K, Ohya Y, Rakugi H, Saito I, Saitoh S, Shimada K, Shimosawa T, Suzuki H, Tamura K, Tanahashi N, Tsuchihashi T, Uchiyama M, Ueda S, Umemura S, Japanese Society of Hypertension Committee for Guidelines for the Management of H (2014) The Japanese society of hypertension guidelines for the management of hypertension (JSH 2014). Hypertens Res 37:253–390
doi: 10.1038/hr.2013.80
Lu J, Frank EL (2007) Measurement of coenzyme Q10 in clinical practice. Clin Chim Acta 384:180–181
doi: 10.1016/j.cca.2007.06.022
Bhagavan HN, Chopra RK (2006) Coenzyme Q10: absorption, tissue uptake, metabolism and pharmacokinetics. Free Radic Res 40:445–453
doi: 10.1080/10715760600617843
Wada H, Dohi T, Miyauchi K, Shitara J, Endo H, Doi S, Naito R, Konishi H, Tsuboi S, Ogita M, Kasai T, Hassan A, Okazaki S, Isoda K, Shimada K, Suwa S, Daida H (2016) Preprocedural high-sensitivity C-reactive protein predicts long-term outcome of percutaneous coronary intervention. Circ J 81:90–95
doi: 10.1253/circj.CJ-16-0790
Ridker PM, Danielson E, Fonseca FA, Genest J, Gotto AM Jr, Kastelein JJ, Koenig W, Libby P, Lorenzatti AJ, MacFadyen JG, Nordestgaard BG, Shepherd J, Willerson JT, Glynn RJ, Group JS (2008) Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. N Engl J Med 359:2195–2207
doi: 10.1056/NEJMoa0807646
Ross R (1999) Atherosclerosis–an inflammatory disease. N Engl J Med 340:115–126
doi: 10.1056/NEJM199901143400207
Bataille R, Klein B (1992) C-reactive protein levels as a direct indicator of interleukin-6 levels in humans in vivo. Arthritis Rheum 35:982–984
doi: 10.1002/art.1780350824
Biasucci LM, Vitelli A, Liuzzo G, Altamura S, Caligiuri G, Monaco C, Rebuzzi AG, Ciliberto G, Maseri A (1996) Elevated levels of interleukin-6 in unstable angina. Circulation 94:874–877
doi: 10.1161/01.CIR.94.5.874
Su D, Li Z, Li X, Chen Y, Zhang Y, Ding D, Deng X, Xia M, Qiu J, Ling W (2013) Association between serum interleukin-6 concentration and mortality in patients with coronary artery disease. Mediators Inflamm 2013:726178
pubmed: 23818744
pmcid: 3683500
Gordon BR, Parker TS, Levine DM, Saal SD, Wang JC, Sloan BJ, Barie PS, Rubin AL (2001) Relationship of hypolipidemia to cytokine concentrations and outcomes in critically ill surgical patients. Crit Care Med 29:1563–1568
doi: 10.1097/00003246-200108000-00011
Chien JY, Jerng JS, Yu CJ, Yang PC (2005) Low serum level of high-density lipoprotein cholesterol is a poor prognostic factor for severe sepsis. Crit Care Med 33:1688–1693
doi: 10.1097/01.CCM.0000171183.79525.6B
Lagrost L, Girard C, Grosjean S, Masson D, Deckert V, Gautier T, Debomy F, Vinault S, Jeannin A, Labbe J, Bonithon-Kopp C (2014) Low preoperative cholesterol level is a risk factor of sepsis and poor clinical outcome in patients undergoing cardiac surgery with cardiopulmonary bypass. Crit Care Med 42:1065–1073
doi: 10.1097/CCM.0000000000000165
Ouchi S, Miyazaki T, Shimada K, Sugita Y, Shimizu M, Murata A, Kato T, Aikawa T, Suda S, Shiozawa T, Hiki M, Takahashi S, Iwata H, Kasai T, Miyauchi K, Daida H (2017) Low docosahexaenoic acid, dihomo-gamma-linolenic acid, and arachidonic acid levels associated with long-term mortality in patients with acute decompensated heart failure in different nutritional statuses. Nutrients 9(9):956
doi: 10.3390/nu9090956
Marinari S, Manigrasso MR, De Benedetto F (2013) Effects of nutraceutical diet integration, with coenzyme Q10 (Q-Ter multicomposite) and creatine, on dyspnea, exercise tolerance, and quality of life in COPD patients with chronic respiratory failure. Multidiscip Respir Med 8:40
doi: 10.1186/2049-6958-8-40
Potgieter M, Pretorius E, Pepper MS (2013) Primary and secondary coenzyme Q10 deficiency: the role of therapeutic supplementation. Nutr Rev 71:180–188
doi: 10.1111/nure.12011
Cocchi MN, Giberson B, Berg K, Salciccioli JD, Naini A, Buettner C, Akuthota P, Gautam S, Donnino MW (2012) Coenzyme Q10 levels are low and associated with increased mortality in post-cardiac arrest patients. Resuscitation 83:991–995
doi: 10.1016/j.resuscitation.2012.03.023